A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Eribulin (Primary) ; Irinotecan
- Indications Solid tumours
- Focus Adverse reactions
- 12 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 15 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Sep 2020.
- 10 Nov 2015 New trial record